Initial clinical trial of a selective retinoid X receptor ligand, LGD1069 Academic Article uri icon

Overview

MeSH Major

  • Anticarcinogenic Agents
  • Neoplasms
  • Tetrahydronaphthalenes

abstract

  • LGD1069 is a unique compound that exploits a newly identified pathway of retinoid receptor biology that may be relevant to tumor-cell proliferation and apoptosis. Further investigation of this drug is warranted. Based on the results of this study, a dose of 300 mg/m2 is recommended for single-agent trials.

publication date

  • February 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 9053506

Additional Document Info

start page

  • 790

end page

  • 5

volume

  • 15

number

  • 2